Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This article discusses the role of external beam radiotherapy as a primary treatment method for cancer and reports no new clinical findings.

Cone beam computed tomography can allow for smaller safety margins around the target area in prostate cancer radiation treatment if used for ongoing treatment checks.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

In this study, SMR-2 and SMR-6, retinoid analogs, were found to be approximately 100 times more toxic than retinoic acid in male mice, primarily affecting skin, immune, and reproductive systems.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study identified the Itpr3 gene as responsible for the tufted hair loss phenotype in the BTBR mouse strain.

CRT is more effective than oral minoxidil alone for treating hair loss.

This review highlights the potential of regenerative medicine therapies, particularly stem cells, in treating a range of chronic diseases and injuries, while also discussing advancements and limitations in their application in Malaysia compared to other Asian countries.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

This study found that bupropion SR may improve symptoms in female trichotillomania patients who did not respond to SSRIs, with benefits maintained through a 16-month follow-up.

This study found that the overexpression of the lncRNA HOTTIP in glioma cells increased resistance to the chemotherapy drug temozolomide, suggesting a key role for miR-10b and EMT processes in this resistance.

This case report describes a 3-year-old boy with trichothiodystrophy, highlighting specific MRI findings of diffuse dysmyelination and osteosclerosis that may be unique to the disorder.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

Ritlecitinib works well and is safe for treating alopecia areata.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This review highlights the potential of transcranial photobiomodulation (tPBM) as a non-invasive and affordable treatment for brain diseases, summarizing recent advances and successful protocols based on over two decades of research.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This study found that methotrexate, when administered according to current recommendations, effectively manages rheumatoid arthritis for many patients in Poland, although regular monitoring is necessary due to possible adverse effects.

This study explored the effects of MOTILIPERM on infertility in a rat model with varicocele and oxidative stress, reporting its potential therapeutic efficacy.